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a b s t r a c t 
A 64-year-old female patient presented with severe dyspnea shortly after apparent recovery 
from COVID-19 disease. Chest computed tomography revealed central pulmonary embolism 
and ultrasonography showed a deep vein thrombosis of her right leg. The patient was tachy- 
cardiac with evidence of right ventricular strain on echocardiography. An interdisciplinary 
decision for interventional therapy was made. 
Angiographic aspiration thrombectomy resulted in a significant reduction of thrombus ma- 
terial and improved flow in the pulmonary arteries and immediate marked clinical improve- 
ment and subsequent normalization of functional echocardiographic parameters. 
This case adds to the emerging evidence for severe thromboembolic complications follow- 
ing COVID-19 and suggests aspiration thrombectomy can be considered in pulmonary em- 
bolism of intermediate risk. 
© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 










Pulmonary embolism (PE) is a potentially fatal condition asso-
ciated with right heart strain and circulatory arrest [1 ,2] . Only∗ Corresponding author. 
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CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/recently has pulmonary embolism been identified to be a se-
rious complication of COVID-19 [3 ,4] . 
Treatment options for PE comprise both systemic ther-
apeutic anticoagulation or lysis, and local therapies [5–7] .
Current guidelines stratify patients with PE into a low-risk
group, best treated with anticoagulation, and a high-risk
group with massive thromboembolism and hypotension in
need of systemic thrombolysis [5] . niversity of Washington. This is an open access article under the 
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 Echocardiography is a highly relevant diagnostic tool for
quantification of right ventricular dysfunction in PE, with
proven prognostic value [8 ,9] . An intermediate-risk group with
submassive PE, that is, right ventricular strain but no hypoten-
sion, might benefit from thrombolysis, since it may prevent
cardiac decompensation [5 ,10] . However, especially in patients
with an intermediate risk, the expected clinical benefit of sys-
temic thrombolysis must be weighed against the bleeding risk
[10] . 
Catheter-directed therapy is considered as an alternative
to systemic treatment [5] . A meta-analysis of catheter-
directed treatment reports a clinical success rate of 86.5%
with a rate of major complications of 2.4% [11] . Complications
of catheter-directed therapies include perforation of the
pulmonary artery or cardiac structures causing tamponade,
stroke, or death [12] . Current data suggest a similar effec-
tiveness of catheter-directed thrombolysis and thrombec-
tomy [13] , which supports an individualized approach with
interdisciplinary discussion. 
Case report 
A 64-year-old female patient presented to the emergency de-
partment of an external hospital with sudden onset of severe
shortness of breath and right leg pain. In the previous 2 weeks,
she had suffered from COVID-19 pneumonia, that is, clinical
diagnosis with a throat swab positive for Sars-Cov-2 infection
in an emergency department. Hospitalization was not recom-
mended at that time. Nine days after onset of her symptoms,
she experienced a significant improvement of fever, weak-
ness, and cough, before her condition deteriorated again 6
days later ( Fig. 1 ). 
She had no preexisting medical conditions and was not
on any regular medication. During her COVID-19 disease, she
took paracetamol occasionally for symptom relief. At that
time, she was ill at home and reduced her daily activities, but
did not maintain bed rest. The patient had recently retired as
a nurse serving on an intermediate care ward. 
Based on the patient’s clinical presentation with tachy-
cardia and shortness of breath, a color-coded Doppler
sonography of the right leg as well as a contrast enhanced
chest computed tomography (CT) scan were performed.
These examinations revealed a deep vein thrombosis in
the right leg and a massive PE mainly affecting the right
pulmonary trunk ( Fig. 2 ). Since the patient was considered to
have intermediate-risk PE with normal blood pressure and
90% oxygen saturation under room air with a moderatelyelevated respiratory rate of 30/min, she was treated by antico-
agulation with unfractionated heparin. As the chest CT scan
also revealed bilateral patchy infiltrates as a sign of bilateral
pneumonia along with an elevated CRP level, the patient was
started on intravenous antibiotic therapy with sultamicillin. 
Due to limited capacity of the hospital to which she ini-
tially presented, she was then transferred to the intensive care
unit (ICU) of our hospital, where she continued to be tachy-
cardic, but normotensive with an oxygen saturation of 96%
at 3-4l oxygen via a breathing mask. The slightest exertion,
even conversation, caused severe dyspnea. Additionally, she
complained about breathing-dependent right thoracic pain.
Transthoracic echocardiography at this time showed a dilated
right ventricle with septal bowing ( Fig. 3 ). A tricuspid annular
plane systolic excursion of 1.9 cm and a hyperdynamic small
left ventricle, along with elevated levels of NT-proBNP (3936
ng/l) and troponin (31 ng/l), indicative of right heart strain. A
positive D-Dimer was at 18.3 mg/l at that time. TSH was nor-
mal at 0.48 mU/l. There was no clinical or laboratory evidence
of hepatic or renal impairment. 
The patient was still considered at intermediate-risk
for PE, as she did not require hemodynamic stabilization.
Furthermore, the possibility was considered that the patient’s
pneumonia might contribute to her severe dyspnea. The
diagnosis of pneumonia was based on imaging findings, that
is, consolidations on CT, no microbiological proof of bacterial
infection was noted. Because of her serious clinical condition
and proven right heart strain, we discussed systemic lysis as
well as other therapeutic approaches. Following interdisci-
plinary consultation, we decided to perform an angiographic
aspiration thrombectomy. 
The patient provided informed consent for the procedure.
Ultrasound indicated a patent left femoral vein, while the
right femoral vein was known to be occluded from thrombo-
sis. After local anesthesia, left femoral venous puncture was
performed for access. The pulmonary trunk was accessed
via the right atrium and chamber using a pigtail catheter
over an inverse and preformed 0.035” stiff guide wire (J-wire).
Angiography confirmed the largest thrombus burden in the
central right pulmonary artery, which was accessed using
a hydrophilic 0.035” guide wire (Radiofocus, Terumo Inter-
ventional Systems, Tokyo, Japan) and a vertebral catheter. A
90-cm long 6F sheath (Destination, Terumo) was advanced to
the level of the right pulmonary artery. Over the stiff Amplatz
wire (Boston Scientific, North Quincy, MA), the aspiration
thrombectomy system (AngioJet, Boston Scientific) was in-
troduced and suction thrombolysis started with 5000 IU of
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Fig. 2 – (A, B) CT scan in axial (A) and coronary (B) reformation at 3 mm, showing central pulmonary embolism and main 
thrombus load in the right pulmonary artery. White arrows pointing at the right pulmonary artery in axial and coronary 
reformation. 
Fig. 3 – (A, B) Preinterventional echocardiography (A) reveals right ventricular enlargement with septal bowing. Following 
aspiration thrombectomy (B), right ventricular strain is reduced with normalization of right/left ventricular ratio (R/V ratio). 










































 unfractionated heparin. Alternatingly, a pigtail catheter was
used to mechanically fractionate the thrombus. As the aspi-
ration time is limited by an increasing risk of hemolysis, the
procedure was only continued until the thrombus burden was
markedly reduced. Eventually, blood flow was significantly
improved both in the right pulmonary artery and in the lung
periphery ( Fig. 4 ). With only residual wall-adherent thrombus
left in the right artery, no thrombolysis catheter for local
thrombolysis was introduced. Catheter material was then
carefully removed with manual compression of the puncture
site. 
During the intervention, the patient received mild seda-
tion only with continuous monitoring by electrocardiography,
invasive blood pressure measurement, and continuous
oxymetry. The procedure was paused repeatedly to mild-
to-moderate cardiac bradyarrhythmia, causing patient
discomfort. The patient’s heart rate normalized immediately
after successful thrombectomy and shortly thereafter the
patient reported a significant improvement of dyspnea. 
During the subsequent monitoring in our ICU, no arrhyth-
mia, bleeding of the puncture site, or any other complica-
tion occurred. Her clinical presentation and global heart func-
tion, as determined by echocardiography, markedly improved.
Accordingly, the previously elevated NTproBNP fell to 1735
ng/l. Anticoagulation therapy was changed to low-molecular
weight heparin with monitoring of anti-Xa activity. Five days later, the patient was transferred back to the regular ward of
the external hospital for further treatment. 
Discussion 
This case report illustrates impressive clinical improvement
following aspiration thrombectomy in a patient with submas-
sive PE due to COVID-19. Also, this adds to the accumulating
evidence for thromboembolic complications of COVID-19 [3] .
The mechanisms inducing enhanced coagulation remain
incompletely understood, but are not confined to severe
courses of the disease [4] . PE remains a serious condition with
high mortality rates despite several treatment options [5] .
With the ongoing SARS-nCoV-2 pandemic, an expected rise
in the number of patients with PE might challenge healthcare
providers. Recent data also imply an increased bleeding risk
for the subgroup of patients with COVID-19 with a high risk
of thromboembolic events [14] . Prophylactic anticoagulation
in patients with COVID-19 – both in severe and in mild cases
as this one – is a current matter of discussion. 
This patient presented with tachycardia and severe dysp-
nea on exertion with echocardiographic evidence of right ven-
tricular strain due to PE, and was therefore treated with anti-
coagulation. As there was no hypotension, we decided against
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Fig. 4 – (A, B) Pulmonary angiography before the intervention (A). After aspiration thrombectomy (B), angiography indicates 
massively reduced thrombotic material in the central right pulmonary artery. Significantly improved perfusion of upper, 
middle, and lower right lobes is noted, resulting in greater efficiency of systemic anticoagulation. Black arrows pointing at 



























 systemic thrombolysis due to an unacceptably high bleeding
risk. An interdisciplinary discussion brought up the possibility
of catheter-directed therapy. The patient was able to provide
informed consent. 
In this patient with submassive PE, we achieved excellent
reperfusion with aspiration thrombectomy alone. Other pa-
tients may require adjunct local thrombolysis, which was con-
sidered unnecessary in this case. After thrombectomy, the pa-
tient’s clinical improvement correlated with the recovery of
cardiac function. One study reports an advantage of catheter-
directed thrombectomy over treatment with anticoagulation
only in patients with submassive PE, as reflected by an im-
provement in the right/left ventricular ratio [15] . Except for
mild to moderate cardiac arrhythmias, the patient tolerated
the procedure well. 
This case supports the hypothesis that patients with
intermediate-risk PE may benefit from catheter-directed ther-
apies such as aspiration-thrombectomy. To our knowledge,
this is the first report of successful treatment of massive PE
with local thrombectomy in a patient with COVID-19. We
believe this option should be considered in centers with
angiographic expertise. Further studies are needed to gain
detailed insights into patient selection and the effectiveness
of specific techniques and devices. 
Written consent to anonymous publication of this case
report was given. 
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